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Conclusions: Endovascular aneurysm repair (EVAR) results in a 3%
better aneurysm-related survival. Compared with open repair, however,
there is no advantage to EVARwith respect to all cause mortality and quality
of life. EVAR is also more expensive and leads to more complications and
reinterventions than open repair.
Summary:The authors sought to determine long-term survival, health
related quality of life, graft durability, and hospital costs with respect to
EVAR and open abdominal aortic aneurysm (AAA) repair. These are mid
term results. A randomized controlled trial of 1,082 patients with AAA at
least 5.5cm in diameter and patient age  60 years was performed. Patients
were considered anatomically suitable for either open repair or EVAR and
were randomized with analysis on an intention to treat basis. The primary
endpoint was all cause mortality. Secondary endpoints were aneurysm
related mortality, postoperative complications, hospital costs, and health
related quality of life.
There were 543 patients randomized to EVAR and 539 patients
randomized to open abdominal aortic aneurysm repair. Of the randomized
patients 1,017 (94%) complied with allocated treatment. At the end of
follow up on December 31, 2004, there were 53 aneurysm related deaths
and 209 overall deaths. All cause mortality 4 years after randomization was
similar in the EVAR and open repair groups (approximately 28%; hazard
ratio 0.90, 95% CI 0.69 – 1.18, P 0.46). There was a persistent reduction
in aneurysm related deaths in the EVAR group (4% versus 7%; hazard ratio
0.55, 95% CI 0.31 - 0.96, P  0.04). Within 4 years of randomization 41%
of patients in the EVAR group had a postoperative complication versus 9% in
the open repair group (hazard ratio 4.9, 95% CI 3.5 – 6.8, P  0.0001).
There were no significant differences in health related quality of life between
the 2 groups after 12months. Hospital costs were higher in the EVAR group
per patient out to 4 years (UK Pounds 13,257 for EVAR versus UK Pounds
9,944 for open repair).
Comment: Both the EVAR trial and the DREAM Study indicate
short-term perioperative survival benefit for endovascular repair of AAA.
Longer term results are disappointing. Clearly, EVAR is not a clear winner
for many patients and certainly not for the healthcare system. I suspect,
however, that it is a clear winner for those companies that manufacture
endovascular grafts. Some will regard this trial and the DREAM Trial as
essentially showing overall equivalence of endovascular and open repair of
AAA. Given this interpretation it is unlikely the results of these two trials will
have any effect on the prevalence of endovascular aneurysm repair for AAA.
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